Expert Interview
Discussing Tris Pharma's Phase 3 results for Alleviate-2, an investigational oral dual-NMR agonist, for the treatment of moderate-to-severe acute pain following bunionectomy surgery.
Ticker(s): TRIS PHARMAInstitution: Sood Medical
- board certified Anesthesiologist specializing in pain medicine
-
manages 100 patients acute pain treatment for bunionectomy and abdominoplasty surgeries
-
familiar with the results from the Phase 2 proof-of-concept studies of VX-548
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
